QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$12.65
+0.17 (+1.36%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.51
$12.66
50-Day Range
$12.42
$13.64
52-Week Range
$11.56
$20.71
Volume
447,286 shs
Average Volume
616,064 shs
Market Capitalization
$882.72 million
P/E Ratio
3.97
Dividend Yield
N/A
Price Target
$13.00

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
2.8% Upside
$13.00 Price Target
Short Interest
Bearish
13.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.50mentions of Innoviva in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-68.86%
From $3.34 to $1.04 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

1022nd out of 1,055 stocks

Pharmaceutical Preparations Industry

501st out of 518 stocks


INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

Innoviva (INVA) Stock Moves -1.06%: What You Should Know
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
Innoviva Completes Acquisition of La Jolla...
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
2/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+2.8%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$265.85 million
Pretax Margin
109.35%

Debt

Sales & Book Value

Annual Sales
$391.87 million
Cash Flow
$4.62 per share
Book Value
$7.56 per share

Miscellaneous

Free Float
69,162,000
Market Cap
$882.72 million
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Pavel Raifeld
    Chief Executive Officer
  • Susan Lenderts
    Director-Strategic Marketing & Analytics
  • Marianne Zhen
    Secretary & Chief Accounting Officer













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2023?

2 brokers have issued 1 year target prices for Innoviva's stock. Their INVA share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 on January 1st, 2023. Since then, INVA shares have decreased by 4.5% and is now trading at $12.65.
View the best growth stocks for 2023 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.75 by $2.15. The biotechnology company had revenue of $67.26 million for the quarter, compared to the consensus estimate of $361.45 million. Innoviva had a trailing twelve-month return on equity of 23.89% and a net margin of 78.39%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.45%), Allspring Global Investments Holdings LLC (0.39%), New York State Common Retirement Fund (0.31%), Exchange Traded Concepts LLC (0.22%), Summit Global Investments (0.20%) and James Investment Research Inc. (0.11%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $12.65.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $882.72 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $3.19 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 1/31/2023 by MarketBeat.com Staff